Hospital
Commonspirit Kansas, INC.
Commonspirit Kansas, INC. was paid $1.22M by Medicaid between Jan 2018 and Nov 2024, across 110 billing codes. Its largest line is 99283, emergency room visit (moderate) — 40% of everything it billed.
33Billing provider infoCOMMONSPIRIT KANSAS, INC.
GARDEN CITY, KS 67846
GARDEN CITY, KS 67846
33aNPI1659360196assigned 10/18/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.22M
24GClaims78,319
24DCodes billed110
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kansas
Rank by total paid#16 of 48
Median peer was paid$461K
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHERT, TADD controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,962 | $239K | |
| 2019 | 8,156 | $128K | |
| 2020 | 7,279 | $109K | |
| 2021 | 9,399 | $137K | |
| 2022 | 11,944 | $228K | |
| 2023 | 14,522 | $204K | |
| 2024incomplete | 11,057 | $173K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 40% | 12,270 | 11,104 | $492K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 3,058 | 2,699 | $126K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5.8% | 706 | 661 | $70K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.8% | 1,642 | 1,529 | $59K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.8% | 12,121 | 10,266 | $46K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.4% | 1,122 | 1,037 | $41K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.1% | 6,884 | 5,821 | $38K |
| 80053 | Comprehensive metabolic panel | 2.8% | 5,235 | 4,368 | $35K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.8% | 1,374 | 1,031 | $34K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 1,946 | 1,548 | $26K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 674 | 536 | $17K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 1,121 | 937 | $14K |
98 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 634 | $13K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.1% | 485 | $13K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 228 | $12K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.0% | 663 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 349 | $10K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 323 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 323 | $9K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 215 | $9K |
| 87400 | <1% | 1,031 | $9K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 763 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 918 | $8K |
| 99285 | Emergency room visit (most serious) | <1% | 127 | $7K |
| 87081 | <1% | 804 | $7K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 731 | $6K |
| 87420 | <1% | 456 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 404 | $4K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 45 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 478 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 635 | $3K |
| 80061 | Lipid panel | <1% | 478 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 53 | $3K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 107 | $3K |
| 83655 | <1% | 218 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 198 | $3K |
| 84439 | <1% | 409 | $3K | |
| 81001 | <1% | 1,136 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 182 | $2K |
| 83690 | <1% | 608 | $2K | |
| G0378 | Hospital observation service, per hour | <1% | 31 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 210 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 24 | $2K |
| 84484 | <1% | 277 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 144 | $2K |
| 83605 | <1% | 173 | $2K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 50 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 139 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 89 | $1K |
| 87807 | <1% | 100 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 32 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 41 | $1K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 76 | $1K |
| 88142 | <1% | 58 | $1K | |
| 86780 | <1% | 72 | $1K | |
| 86850 | <1% | 150 | $1K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14 | $954.86 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 57 | $933.67 |
| 86140 | <1% | 129 | $865.39 | |
| 85027 | <1% | 88 | $862.49 | |
| 94664 | <1% | 59 | $781.98 | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 13 | $768.10 |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 201 | $745.67 |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,466 | $722.11 |
| 87077 | <1% | 72 | $637.88 | |
| 87070 | <1% | 130 | $571.57 | |
| 86901 | <1% | 105 | $510.42 | |
| 81025 | <1% | 70 | $495.55 | |
| 83970 | <1% | 42 | $478.11 | |
| 74018 | <1% | 46 | $462.63 | |
| 97161 | <1% | 13 | $446.95 | |
| 87186 | <1% | 46 | $439.87 | |
| 73610 | <1% | 35 | $433.23 | |
| 86900 | <1% | 105 | $404.16 | |
| 87340 | <1% | 28 | $383.90 | |
| 86762 | <1% | 59 | $378.29 | |
| 85610 | <1% | 91 | $355.89 | |
| 86738 | <1% | 48 | $334.10 | |
| 84703 | <1% | 52 | $327.76 | |
| 74019 | <1% | 19 | $313.88 | |
| 73630 | <1% | 18 | $309.45 | |
| 81003 | <1% | 283 | $305.77 | |
| 82570 | <1% | 80 | $246.88 | |
| 86803 | <1% | 14 | $219.43 | |
| 83735 | <1% | 42 | $205.45 | |
| 73030 | <1% | 14 | $187.08 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 339 | $162.47 |
| 87045 | <1% | 12 | $153.34 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 158 | $125.38 |
| 84156 | <1% | 54 | $102.88 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 589 | $70.98 |
| 85018 | <1% | 36 | $61.44 | |
| 85651 | <1% | 12 | $43.26 | |
| 85014 | <1% | 24 | $39.33 | |
| 84550 | <1% | 14 | $39.30 | |
| 84100 | <1% | 16 | $37.92 | |
| 87427 | <1% | 16 | $35.44 | |
| 82248 | <1% | 15 | $33.04 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 62 | $32.09 |
| 82043 | <1% | 12 | $25.90 | |
| J2704 | Injection, propofol, 10 mg | <1% | 184 | $24.40 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 120 | $10.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 173 | $3.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 22 | $0.30 |
| G0008 | Administration of influenza virus vaccine | <1% | 33 | $0.01 |
| 90662 | 0% | 12 | $0.00 | |
| 82077 | 0% | 15 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 113 | $0.00 |
| 90686 | 0% | 14 | $0.00 | |
| 80050 | General health panel | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHERT, TADD (REGION CHIEF FINANCIAL OFFICER)
Parent organizationCOMMONSPIRIT HEALTH
| Provider | Location | Paid |
|---|---|---|
| Catholic Health Initiatives Colorado | Colorado Springs, CO | $25.26M |
| Catholic Health Initiatives Colorado | Pueblo, CO | $23.66M |
| Catholic Health Initiatives Colorado | Lakewood, CO | $8.91M |
| Catholic Health Initiatives Colorado | Canon City, CO | $8.35M |
| Catholic Health Iniatives Colorado | Westminster, CO | $7.55M |
| Catholic Health Initiatives Colorado | Canon City, CO | $6.39M |
| Catholic Health Initiatives Colorado | Durango, CO | $5.98M |
| Longmont United Hospital | Longmont, CO | $5.25M |
| Catholic Health Initiatives Colorado | Lakewood, CO | $4.40M |
| Commonspirit Kansas, INC. | Ulysses, KS | $2.77M |
| Catholic Health Initiatives Colorado | Fort Morgan, CO | $1.17M |
| Catholic Health Iniatives Colorado | Frisco, CO | $691K |
| ST. Vincent Infirmary Medical Center | Sherwood, AR | $469K |
| Commonspirit Kansas, INC. | Dodge City, KS | $267K |
| Catholic Health Initiatives Colorado | Pueblo, CO | $153K |
| Catholic Health Initiatives Colorado | Colorado Springs, CO | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.